Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine.
Adult
Attention
/ drug effects
Caffeine
/ pharmacology
Central Nervous System Stimulants
/ pharmacology
Cognition
/ drug effects
Double-Blind Method
Fatigue
/ prevention & control
Humans
Male
Methylphenidate
/ pharmacology
Modafinil
/ pharmacology
Nootropic Agents
/ pharmacology
Pilot Projects
Treatment Outcome
Young Adult
Caffeine
Cognitive enhancement
Methylphenidate
Modafinil
Neuroenhancement
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
20
05
2020
accepted:
23
10
2020
pubmed:
18
11
2020
medline:
27
2
2021
entrez:
17
11
2020
Statut:
ppublish
Résumé
At all times humans have made attempts to improve their cognitive abilities by different means, among others, with the use of stimulants. Widely available stimulants such as caffeine, but also prescription substances such as methylphenidate and modafinil, are being used by healthy individuals to enhance cognitive performance. There is a lack of knowledge on the effects of prescription stimulants when taken by healthy individuals (as compared with patients) and especially on the effects of different substances across different cognitive domains. We conducted a pilot study with three arms in which male participants received placebo and one of three stimulants (caffeine, methylphenidate, modafinil) and assessed cognitive performance with a test battery that captures various cognitive domains. Our study showed some moderate effects of the three stimulants tested. Methylphenidate had positive effects on self-reported fatigue as well as on declarative memory 24 hours after learning; caffeine had a positive effect on sustained attention; there was no significant effect of modafinil in any of the instruments of our test battery. All stimulants were well tolerated, and no trade-off negative effects on other cognitive domains were found. The few observed significant positive effects of the tested stimulants were domain-specific and of rather low magnitude. The results can inform the use of stimulants for cognitive enhancement purposes as well as direct further research to investigate the effects of stimulants on specific cognitive domains that seem most promising, possibly by using tasks that are more demanding.
Identifiants
pubmed: 33201262
doi: 10.1007/s00213-020-05691-w
pii: 10.1007/s00213-020-05691-w
pmc: PMC7826302
doi:
Substances chimiques
Central Nervous System Stimulants
0
Nootropic Agents
0
Methylphenidate
207ZZ9QZ49
Caffeine
3G6A5W338E
Modafinil
R3UK8X3U3D
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
441-451Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : 3322/1-1
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB 936/C7
Organisme : H2020 European Research Council
ID : ERC-2016-StG-Self-Control-677804
Organisme : Jacobs Foundation
ID : JRF 2016-2018
Organisme : Volkswagen Foundation
ID : 85648
Références
Psychopharmacology (Berl). 2018 Feb;235(2):467-479
pubmed: 28551715
Pharmacol Rev. 2013 Dec 16;66(1):193-221
pubmed: 24344115
J Pers Soc Psychol. 1988 Jun;54(6):1063-70
pubmed: 3397865
Eur Neuropsychopharmacol. 2017 Mar;27(3):248-260
pubmed: 28119083
Psychopharmacology (Berl). 2013 Jan;225(2):251-74
pubmed: 23241646
Physiol Behav. 2015 Nov 1;151:629-37
pubmed: 26320858
Neuropsychopharmacology. 2008 Jun;33(7):1477-502
pubmed: 17712350
Science. 2015 Oct 23;350(6259):379-80
pubmed: 26494744
Addiction. 2016 Feb;111(2):280-95
pubmed: 26189457
Int J Neuropsychopharmacol. 2017 Sep 1;20(9):712-720
pubmed: 28525569
Pharmacol Biochem Behav. 2005 Sep;82(1):133-9
pubmed: 16140369
Neuron. 2017 Mar 8;93(5):1227-1235.e6
pubmed: 28279356
Neuropharmacology. 2013 Jan;64:529-43
pubmed: 22828638
Psychopharmacology (Berl). 2010 Jun;210(3):317-29
pubmed: 20352415
ACS Chem Neurosci. 2019 Mar 20;10(3):1137-1148
pubmed: 30550256
Psychopharmacology (Berl). 2012 Jun;221(4):611-9
pubmed: 22169884
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Am J Psychiatry. 2018 Aug 1;175(8):741-755
pubmed: 29656665
J Cogn Neurosci. 2015 Jun;27(6):1069-89
pubmed: 25591060
Eur Arch Psychiatry Clin Neurosci. 2014 Nov;264 Suppl 1:S83-90
pubmed: 25214391
Neurosci Biobehav Rev. 2003 Nov;27(7):615-21
pubmed: 14624806
PLoS One. 2015 Dec 10;10(12):e0144402
pubmed: 26657300
Eur Neuropsychopharmacol. 2014 Feb;24(2):200-6
pubmed: 24119823
J Psychopharmacol. 2014 Sep;28(9):847-56
pubmed: 25052243
Nat Rev Neurosci. 2006 Jun;7(6):477-84
pubmed: 16688123
J Cogn Neurosci. 2009 Mar;21(3):529-37
pubmed: 18564044
Neuropharmacology. 2018 May 15;134(Pt A):133-140
pubmed: 28823611
Cortex. 2007 Jul;43(5):635-50
pubmed: 17715798
Eur Neuropsychopharmacol. 2015 Nov;25(11):1865-81
pubmed: 26381811
J Neurosci. 2000 Mar 15;20(6):RC65
pubmed: 10704519
J Clin Psychopharmacol. 2009 Oct;29(5):439-43
pubmed: 19745643
Curr Neuropharmacol. 2015 Jan;13(1):71-88
pubmed: 26074744
Am J Psychiatry. 1998 Oct;155(10):1325-31
pubmed: 9766762
J Am Acad Child Adolesc Psychiatry. 2008 Jan;47(1):21-31
pubmed: 18174822
Int J Neuropsychopharmacol. 2018 Apr 1;21(4):345-354
pubmed: 29206921
Pharmacol Res. 2010 Sep;62(3):187-206
pubmed: 20416377
JAMA. 2009 Mar 18;301(11):1148-54
pubmed: 19293415
J Clin Exp Neuropsychol. 2010 Oct;32(8):871-80
pubmed: 20383801